Molecular diagnostic company adds senior-level positions, continues expansion of management team
ITHACA, N.Y. Rheonix Inc., developer of automated molecular diagnostic platforms and consumables, has added Frank Gill as vice president of manufacturing. In this role, Gill will be responsible for formulating and executing the company's operations strategy as it scales from prototype volumes to fully automated production of life science and in vitro diagnostics products.
Gill will oversee manufacturing of Rheonix instrument platforms, reagent kits and the Rheonix CARD® system, a powerful automated microfluidic platform capable of analyzing raw samples in a variety of applications.
"We are very excited to bring Frank on board at Rheonix," said Tony Eisenhut, president of Rheonix. "With his ability to take discovered technology to an operational level and implement scalable manufacturing processes, he will be a tremendous asset in helping to execute our upcoming strategies."
Gill has more than 15 years of experience building operational and supply chain infrastructure for early-stage companies in the biotech, life sciences and medical device fields. Most recently, he was director, reagent manufacturing operations at 454 Life Sciences, a division of the Roche Group, and has held similar positions at Immunicon (now Veridex) and Songbird Hearing Inc. Gill earned a bachelor's degree from Albright College.
"I look forward to helping a growing company like Rheonix take its unique technology out of the research and development lab and translate it into an operational, manufacturing process able to meet the scale and volume demands of our applied and clinical markets," Gill said. "I'm excited to join this proven management team and help bring novel solutions to address the need for rapid, sensitive and efficient tools for the food safety and clinical IVD markets."
Rheonix Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. Rheonix, through experienced leadership and creative vision, has developed the EncompassMDx platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD® and EncompassMDx family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in between. For more information, visit www.rheonix.com
Public Relations Account Manager
Pinckney Hugo Group
760 West Genesee Street
Syracuse, NY 13204
On behalf of Rheonix